GOLETA, Calif. — Inogen, Inc. (Nasdaq:INGN) announced today that it has received FDA clearance for an innovative home oxygen concentrator called the Inogen At Home.
Inogen narrowed the price range for the initial public offering it registered late last year, saying it expects to price the IPO at $16 to $18 per share.
That would make the 4.4-million-share offering worth $70.6 million to $79.4 million; if the shares sell at the midpoint, Inogen would raise about $75.0 million.
Inogen registered for an initial public offering worth up to $86.3 million IPO, saying it plans to will trade on the NASDAQ exchange under the INGN symbol.
The Goleta, Calif.-based medical device company makes oxygen concentrators used to deliver supplemental oxygen therapy to patients suffering from chronic respiratory conditions.